Ann Clin Diabetes Endocrinol | Volume 4, Issue 1 | Review Article | Open Access

Renal Outcomes with Anti-Diabetic Medications and Clinical Implications in Type 2 Diabetes

Zafar S1, Latif MM1, Rahman MM1, Gundre P2, Kodumuri V3 and Bondugulapati LNR1

1Department of Endocrinology, Maelor Hospital, UK
2Department of Critical Care, Sunrise Hospital and Medical Center, USA
3Department of Cardiology, Ascension All Saints Hospital, USA

*Correspondance to: Bondugulapati LNR, 

Fulltext PDF


After the invention of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers (ACE-i/ARB), for nearly two decades, there has not been another drug to prevent the progression of diabetic kidney disease. Recent trials have indicated that some of the anti-hyperglycemic drug classes have positive renal outcomes thus potentially changing the course of renal disease. Here, we summarized the relevant evidence with medications used in diabetes mellitus, especially focusing on the most recent innovations predominantly used in type-2 diabetes.


Diabetes mellitus; Diabetic nephropathy; Albuminuria; Chronic kidney disease; SGLT-2 inhibitors; GLP-1 agonists


Zafar S, Latif MM, Rahman MM, Gundre P, Kodumuri V, Bondugulapati LNR. Renal Outcomes with Anti- Diabetic Medications and Clinical Implications in Type 2 Diabetes. Ann Clin Diabetes Endocrinol. 2021;4(1):1022.

Subscribe to Our Newsletter